MLN2238 is a proteasome inhibitor. Much like Bortezomib, MLN2238 selectively and reversibly inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome, with IC50 and Ki of 3.4 nM and 0.93 nM, respectively. MLN9708 is the prodrug form of MLN2238; the two compounds are also known as ixazomib citrate and ixazomib, respectively. Under physiological conditions, the boronic citrate ester is rapidly hydrolyzed to a boronic acid. Ixazomib has been used in combination therapy as a treatment for multiple myeloma, and studies indicate that it has the potential to treat other cancers as well.
|Purity||>99% (HPLC), NMR (conforms)|
|Molecular Weight||361.03 Da|
|Physical State||Lyophilized powder|
|Solubility||DMSO (72 mg/mL); ethanol (9 mg/mL)|
|Storage||4°C, (-20°C Long term). The product can be shipped at room temperature.|